| Detected | Trial | Change |
|---|---|---|
| 2026-06-03 | NCT07424287 A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected… |
Primary endpoint(s) modified |
| 2026-05-14 | NCT07489716 A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer |
Recruitment opened |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07229625 | A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing… | Advanced Biliary Tract Cancer | Recruiting |
| NCT07118527 | A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in… | Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma | Recruiting |
| NCT07393542 | A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial… | Locally Advanced or Metastatic Urothelial Carcinoma | Recruiting |
| NCT07418749 | A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With… | Recurrent Cervical Cancer | Recruiting |
| NCT07183189 | A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line… | Non-small Cell Lung Cancer | Recruiting |
| NCT06618664 | A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab… | Advanced Hepatocellular Carcinoma | Recruiting |
| NCT06671379 | A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or… | Non-small Cell Lung Cancer | Active, Not Recruiting |
| NCT07424287 | A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected… | NMIBC | Not Yet Recruiting |
| Phase 2/3 | |||
| NCT07454720 | A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as… | Locally Advanced Resectable Rectal Cancer | Recruiting |
| Phase 2 | |||
| NCT07028268 | A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors | For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors | Recruiting |
| NCT07110571 | A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as… | Gastric Cancer | Recruiting |
| NCT05671822 | Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2… | HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | Recruiting |
| NCT07028281 | A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid… | Malignant Solid Tumors | Recruiting |
| NCT07071714 | A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in… | Colorectal Cancer | Recruiting |
| NCT07450976 | A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer | Biliary Tract Cancer | Recruiting |
| NCT07489716 | A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Recruiting |
| NCT06465563 | SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as… | Biliary Tract Cancer | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06737731 | A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid… | Malignant Solid Tumors | Recruiting |
| NCT07239596 | Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor… | Advanced Renal Cell Carcinoma | Recruiting |
| NCT07229638 | A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in… | Solid Tumor | Recruiting |
| NCT07298772 | A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients… | Advanced Solid Tumor | Recruiting |
| Phase 1 | |||
| NCT07275242 | A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor | Solid Tumor | Recruiting |
| NCT07123129 | A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors | Advanced Malignancy | Recruiting |
| NCT07414602 | A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects | Dermatitis | Recruiting |
| NCT06484777 | A Clinical Study of SHR-9539 in Patients With Multiple Myeloma | Multiple Myeloma | Recruiting |